The Treatment Burden of Myopic Choroidal Neovascularization

Pathologic myopia (PM) is characterized by progressive eye elongation associated with degenerative changes in the retinal and choroidal tissue. Myopic choroidal neovascularization (mCNV) is a well-known complication of PM, occurring in 5-11% of cases and representing a main cause of visual impairment in working people under the age of 50. The management of patients affected by active mCNV have been revolutionized by the advent of intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) drugs. Patients affected by mCNV needs intravitreal injections and visits to assess the need of retreatment with assiduity. It represents a significant burden for patients, caregivers as well as medical equipe. The aim of this study is to investigate the factors associated with the number of anti-VEGF injections and hospital visits necessary to get mCNV disease stabilization and to identify predictive factors of treatment burden.

NCT Number	NCT07009574
Lead Sponsor	Policlinico Gaspare Rodolico - San Marco Catania
Conditions	Myopic Choroidal Neovascularisation, Anti-VEGF Treatment, Burden
Enrollment	100 participants
Start Date	2025-06-01
Primary Completion	2025-12-01 (estimated)
Study Completion	2025-12-15 (estimated)
Updated on ClinicalTrials.gov	2025-06-06